Milestone Pharmaceuticals Inc.(MIST)

$1.22—

Chart

Milestone Pharmaceuticals Inc.(MIST)

NASDAQ

$1.22—

Chart Studio

MIST(MIST)

MIST

Overview Notebook Intelligence Chart History Fundmntls TTM Earnings Analysts News Financials Segments Insiders Institl.DCF Peers

Q3 2026 EPS Estimate

$-0.18

Aug 12, 2026 · Reports before open

Revenue Estimate

$1M

FY2029E EPS$0.10

FY2030E EPS$0.59

Analyst Sentiment

Wall St. Consensus

Buy

7 analysts·Limited coverage

Score

6 Buy (86%)1 Hold (14%)0 Sell (0%)

Rating Breakdown

Strong Buy

00%

Buy

686%

Hold

114%

Sell

00%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear

$6.00

+391.8%

Consensus

$6.00

+391.8%

Bull

$6.00

+391.8%

12-Month Target Range7 analysts

$6.00$6.00$6.00

Current $1.22Consensus

Current Price

$1.22

Upside to Consensus

$4.78

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)

FY2027

Rev+315.07%

EPS—

FY2028

Rev+352.30%

EPS—

FY2029

Rev+66.06%

EPS—

Raw consensus estimates (low / average / high) from covering analysts.

Annual

Metric	FY2026E	FY2027E	FY2028E	FY2029E	FY2030E
Revenue Avg	$7M	$29M	$133M	$221M	$308M
Low	$5M	$26M	$102M	$169M	$235M
High	$8M	$34M	$170M	$283M	$393M
EBITDA Avg	$-4M	$-18M	$-80M	$-133M	$-185M
Low	$-5M	$-21M	$-102M	$-170M	$-236M
High	$-3M	$-16M	$-61M	$-102M	$-141M
EBIT Avg	$-4M	$-18M	$-80M	$-133M	$-185M
Low	$-5M	$-21M	$-102M	$-170M	$-236M
High	$-3M	$-16M	$-61M	$-102M	$-141M
Net Income Avg	$-78M	$-86M	$-35M	$9M	$49M
Low	$-125M	$-143M	$-48M	$6M	$34M
High	$-60M	$-57M	$-24M	$12M	$67M
EPS Avg	$-0.93	$-1.02	$-0.42	$0.10	$0.59
Low	$-1.50	$-1.70	$-0.57	$0.07	$0.41
High	$-0.71	$-0.68	$-0.29	$0.14	$0.80
Analysts (Rev / EPS)	4 / 4	4 / 4	2 / 3	3 / 2	3 / 2

Quarterly

Metric	Q3 2026	Q4 2026	Q1 2027	Q2 2027	Q3 2027	Q4 2027
Revenue Avg	$2M	$4M	$5M	$6M	$8M	$10M
Low	$1M	$2M	$3M	$3M	$4M	$5M
High	$3M	$5M	$7M	$9M	$10M	$13M
EBITDA Avg	$-1M	$-2M	$-3M	$-4M	$-5M	$-6M
Low	$-2M	$-3M	$-4M	$-5M	$-6M	$-8M
High	$-759,202	$-1M	$-2M	$-2M	$-2M	$-3M
EBIT Avg	$-1M	$-2M	$-3M	$-4M	$-5M	$-6M
Low	$-2M	$-3M	$-4M	$-5M	$-6M	$-8M
High	$-759,202	$-1M	$-2M	$-2M	$-2M	$-3M
Net Income Avg	$-27M	$-29M	$-27M	$-28M	$-29M	$-30M
Low	$-34M	$-42M	$-40M	$-41M	$-43M	$-44M
High	$-23M	$-12M	$-11M	$-11M	$-12M	$-12M
EPS Avg	$-0.21	$-0.22	$-0.21	$-0.22	$-0.23	$-0.23
Low	$-0.26	$-0.32	$-0.31	$-0.32	$-0.33	$-0.34
High	$-0.18	$-0.09	$-0.08	$-0.09	$-0.09	$-0.09
Analysts (Rev / EPS)	4 / 4	3 / 2	3 / 2	2 / 1	2 / 1	3 / 2

Earnings Surprises

Recent Analyst Actions

Apr 10, 2026Raymond James

Milestone Pharmaceuticals initiated with a Strong Buy at Raymond James

Target:$6.00

+193.5%from $2.04

Dec 16, 2025Wells Fargo

Milestone Pharmaceuticals price target raised to $8 from $4 at Wells Fargo

Target:$8.00

+241.9%from $2.34

Dec 15, 2025H.C. Wainwright

Milestone Pharmaceuticals price target raised to $8 from $5 at H.C. Wainwright

Target:$8.00

+210.7%from $2.58

Apr 22, 2022Piper Sandler

Piper Sandler Upgrades Milestone Pharmaceuticals to Overweight, Raises Price Target to $10

Target:$10.00

+39.9%from $7.15

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance